Five years after COVID, pharma shares languish in US policy limbo

Global healthcare stocks are trading at their deepest discount in 16 years, 20% below global equities, primarily due to policy uncertainty surrounding potential U.S. drug pricing and import tariffs under the Trump administration. This limbo has obscured earnings outlooks and led to a post-COVID investor exodus, despite recent net inflows into healthcare funds. While some investors are selectively increasing exposure, citing strong cash flows and long-term demographic tailwinds, the sector remains cheap and unloved, awaiting clear policy catalysts to trigger a broad re-rating.

Analysis

The global healthcare sector is trading at its most significant valuation discount in 16 years, with the MSCI World Health Care Index priced at a 20% discount to global equities and a forward P/E of 15.9. This underperformance is primarily driven by acute policy uncertainty in the United States, specifically the potential revival of "most-favored-nation" drug pricing rules and proposed 200% import tariffs, which obscure the earnings outlook for major pharmaceutical companies. Consequently, U.S. healthcare stocks have underperformed the S&P 500 by over 60 percentage points in the last three years, deepening their valuation discount to a near-record 27%. Despite a post-pandemic investor exodus to technology, there are signs of renewed interest, with healthcare funds seeing $7.2 billion in net inflows year-to-date. Some investors are looking past the political overhang to focus on long-term drivers like aging populations, innovative pipelines in RNA and weight-loss drugs, and the potential for interest rate cuts to lower funding costs. However, the consensus remains that the sector's cheapness is not a sufficient catalyst for a re-rating; a resolution to the policy uncertainty is required to unlock value and potentially spur M&A activity. In the interim, a divergence is emerging, with some portfolio managers favoring smaller, innovative firms like Alnylam and Penumbra that are reaching profitability, over large-cap pharma more exposed to pricing and patent risks.

Key Decisions for Investors

• Investors should recognize that the healthcare sector's performance is currently tethered to U.S. political outcomes, making any clear signal on drug pricing or tariff policy the most critical catalyst for a potential re-rating.
• Consider a selective, stock-specific approach rather than broad sector exposure, potentially favoring innovative small-to-mid-cap companies transitioning to profitability or those with strong cash flows and defensive characteristics.
• Monitor companies' strategic responses to tariff risks, such as AstraZeneca's $50 billion U.S. investment, as adaptive supply chain management will be a key differentiator.
• Acknowledge that while the sector appears fundamentally cheap, it may remain a value trap until the policy overhang clears; long-term investors may find entry points, but near-term volatility is expected to persist.